Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002169 · ClinicalTrials.gov registry record · Phase 2

A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis

A Phase 2 study of HIV Infections and Cytomegalovirus Retinitis, sponsored by Agouron Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
8
Study locations

NCT00002169: Completed Phase 2 study of HIV Infections and Cytomegalovirus Retinitis, sponsored by Agouron Pharmaceuticals.

NCT00002169 is a Phase 2 study of HIV Infections and Cytomegalovirus Retinitis that has completed, run by Agouron Pharmaceuticals. The trial reports 8 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002169, a Phase 2 study of HIV Infections and Cytomegalovirus Retinitis, has completed, sponsored by Agouron Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
8
Study locations

Study Summary

The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are already being treated for cytomegalovirus (CMV) retinitis.

Conditions Studied

HIV Infections Cytomegalovirus Retinitis

Interventions

  • DRUG Nelfinavir mesylate

Study Locations (8)

California

  • Univ of Southern California / LA County USC Med Cntr - Los Angeles
  • Univ of California / UCI Med Ctr - Orange
  • Univ of California / San Diego Treatment Ctr - San Diego
  • Harbor UCLA Med Ctr - Torrance

Texas

  • Univ of Texas Med Branch - Galveston
  • Baylor Univ - Houston

District of Columbia

  • George Washington Univ - Washington D.C.

Illinois

  • Northwestern Univ / SOCA - Chicago

Trial Details

FieldValue
Phase Phase 2
Agouron Pharmaceuticals

10 total trials

What the finished NCT00002169 record still lists

NCT00002169 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Nelfinavir mesylate is the first listed.

NCT00002169 lists 8 locations in 4 states (California, Texas, District of Columbia).

Frequently Asked Questions

What is clinical trial NCT00002169 about?

NCT00002169 is a clinical study titled "A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis". The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are already being treated for cytomegalovirus (CMV) retinitis.

What is the current status of trial NCT00002169?

This trial is currently completed. It is a Phase 2 study.

What conditions does trial NCT00002169 study?

This clinical trial studies the following conditions: HIV Infections, Cytomegalovirus Retinitis.

What interventions are being tested in trial NCT00002169?

The interventions under investigation include: Nelfinavir mesylate (DRUG).

Who is sponsoring clinical trial NCT00002169?

This trial is sponsored by Agouron Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002169 being conducted?

This trial has 8 study locations across California, District of Columbia, Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002169, the US trial registry maintained by the National Library of Medicine. NCT00002169 (unsized enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.